Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Citigroup's Yigal Nochomovitz raised their price target on Arvinas (NASDAQ: ARVN) by 20% from $15 to $18 on 2026/03/05. The analyst maintained their Strong Buy rating on the stock.

Arvinas reported its Q4 and FY 2025 earnings.

Nochomovitz attributed their price target move to the quarter's results.

Earnings Report

Arvinas reported:

For Q4 2025:

• EPS of $(1.10), which missed the Zacks Consensus Estimate of $(0.55) and Q4 2024's $(0.63).
• Revenue of $9.5M, which missed the Zacks Consensus Estimate by 71.26% and Q4 2024's $59.2M.

For FY 2025:

• EPS of $(1.14), up from FY 2024's $(2.63).
• Revenue of $262.6M, down from FY 2024's $263.4M.

Management guided that it has sufficient funds for planned operating expenses and capital expenditure requirements into 2H 2028.

President & CEO Randy Teel, Ph.D., commented: “2025 was marked by meaningful progress across our pipeline and was a truly transformative year for the Company.

“In addition to submitting our first new drug application, which sets the stage for the potential first-ever FDA approval of a PROTAC degrader, we redefined our strategic path and sharpened our focus within our pipeline to maximize the compelling opportunities ahead in each of our core areas of focus.

"With four ongoing clinical trials across our oncology and neurology portfolios, including the recently initiated first-in-human trial of our polyQ-AR degrader, ARV-027, we believe we have the potential to bring truly differentiated treatments to millions of patients in areas of significant unmet medical need.”